Arbutus Biopharma (ABUS) Reports In-Line Q1 EPS

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
• Academy Sports & Outdoors Inc. (ASO) PT Raised to $47 at BMO Capital